Medical Marijuana Is Undervalued At 3.2x Forward Sales

516

With Q1 revenue growing at 92% y/y and a gross profit of 78%, Medical Marijuana (OTCPK:MJNA) recently surprised the market. The quarterly results were beneficial, and the company is undervalued at 3.2x forward sales. Other competitors are trading at much higher valuations. If MJNA continues delivering favorable revenue growth, the share price should increase. Market participants will most likely accept paying $0.21 per share.

Business Model
Medical Marijuana Inc. is focused on the development, sale, and distribution of hemp oil containing cannabinoids.

It is impossible to review all the hemp oil products offered by MJNA. With that, let’s mention a few facts that are making MJNA a leader in the sector. The company offers free shipping and guarantees that the entire hemp oil delivered is produced in ISO-certified facilities. Besides, shareholders obtain 20% discount when they acquire products. The image below was taken from

Ga naar Bron